Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

cokinetic study on weekly oral AEZS-112, a small molecule anti-cancer agent in patients with advanced cancer and lymphoma", was presented by D. W. Northfelt, M.D.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 The Activated Carbon ... which is why IBISWorld updated its original industry research ... benefit from an intensified focus on environmental policy. Over ... emission standards for power plants and a range of ... IBISWorld Industry Analyst Sarah Kahn, “a range of downstream ...
(Date:12/17/2014)... Once more, EMAAR has selected ... waste water treatment plant to phase one of BayLaSun, ... Two years ago Bioshaft successfully supplied and operated a ... residential towers with an occupancy of 900 residences. ... gallons per day and was signed on September 16th, ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... ... Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes, ... ATR-FTIR spectra for the production and control of qualitative supersaturation trajectories. , ... (PRWEB) October 9, 2009 -- ...
... PALO ALTO, Calif., Oct. 8 CardioDx, a cardiovascular ... G. Lange, M.D., Ph.D., as Chairman of the company,s ... first and only gene expression test to quantify the ... with stable chest pain. , "Dr. Lange brings ...
... WORTH, Texas, Oct. 8 Guacamole is a little ... and deli sections introduce Wholly "Pink" Guacamole. Nielsen-ranked, top-selling ... row, donating 15 percent of proceeds from October "PINK" ... pretty-in-pink box is a reminder of Texas-Based Wholly,s support ...
Cached Biology Technology:Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 2CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors 2CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors 3Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... that the dawn of agriculture may have come with ... some 11,400 years ago, roughly a thousand years before ... in the region. The discovery dates domesticated figs to ... making the fruit trees the oldest known domesticated crop. ...
... combining the four bacterial surface proteins that generate ... the University of Chicago have created a vaccine ... drug-resistant strains of Staphylococcus aureus, the most common ... source of community-associated illness. , The vaccine ...
... June 15th issue of G&D, Dr. Marie-Louise Hammarskjold (UVA) ... the Wilms' Tumor 1 tumor suppressor. The Wilms' Tumor ... pathological human development, with known roles in kidney and ... , Dr. Hammarskjold and colleagues reveal that WT1 works ...
Cached Biology News:Tamed 11,400 years ago, figs were likely first domesticated crop 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3
... as a wash buffer for Michels Transport Fluid ... for transportation of specimens (such as renal biopsies ... may remain in Transport Fluid for up to ... Fluid is not a fixative and is not ...
... sizes available for use with 96- or 384-well PCR ... for ease of location on 96-tube plates End ... skirt of the plate* Efficient sealing is achieved ... conjunction with screw or clip-down hot lid thermal cyclers ...
... provides complete components including positive and negative ... fragmentation in cultured cells and tissue sections. ... provides greater sensitivity than biotinylated or digoxigenylated ... cytometry. The kit works well with GFP ...
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
Biology Products: